CIK 0001725160
- Non-accelerated filer
- Smaller reporting company
Zentalis Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ZNTL
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823607803
- Phone
- +1 858-263-4333
- Business address
- 10275 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- Zentalis Pharmaceuticals, LLC, Zeno Pharma, LLC
- 4 Grant or award Director acquired 260,192 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Principal Accounting Officer sold 1,603 shares at $3.18 ($5,098)
- 4 Grant or award Director acquired 41,581 shares (grant or award)
- 4 Grant or award Director acquired 41,581 shares (grant or award)
- 4 Grant or award Director acquired 48,429 shares (grant or award)
- 4 Open-market sale President, Interim CFO sold 9,597 shares at $11.98 ($114,972)
- 4 Grant or award Director acquired 72,481 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Medical Officer sold 3,356 shares at $12.62 ($42,353)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Financial Officer sold 2,573 shares at $11.44 ($29,435)
- 4 Open-market sale President sold 1,173 shares at $11.44 ($13,419)
- 4 Grant or award Chief Medical Officer acquired 337,500 shares (grant or award)
- 4 Open-market sale Chief Scientific Officer sold 1,585 shares at $11.54 ($18,291)
- 4 Open-market sale Chief Legal Officer sold 3,310 shares at $11.54 ($38,197)
- 4 Open-market sale President sold 11,552 shares at $11.54 ($133,310)
- 4 Open-market sale Chief Financial Officer sold 8,669 shares at $11.54 ($100,040)
Page 3 of 13 · 252 filings